ABCs in Dermatology: Previewing the 2026 AAD Annual Meeting

Welcome back to ABCs in Dermatology!

The 2026 American Academy of Dermatology (AAD) Annual Meeting convenes in Denver with a scientific agenda promising to showcase the latest advances and breakthroughs in dermatologic care.

In this preview episode of ABCs in Dermatology, hosts Chris Bunick, MD, PhD, of Yale School of Medicine, and Lindsay Ackerman, MD, of US Dermatology Partners, survey the landscape ahead of the meeting and walk through the sessions each will be presenting on-site.

HOST SESSIONS AT AAD 2026

Session: Acne & Rosacea
Date: Friday, March 27, 2026

Session Summary

Bunick reframes antibiotics in acne as anti-inflammatory agents rather than antimicrobials—a distinction he argues is clinically meaningful for patient adherence and prescribing confidence. The talk addresses antibiotic stewardship, the role of narrow-spectrum agents such as sarecycline in preserving gut microbiome integrity while retaining full anti-inflammatory efficacy, and the understudied pathophysiologic distinctions between teenage and adult female acne. Sarecycline's inability to cross the blood-brain barrier, minimal vestibular disturbance, and lowest resistance profile among tetracyclines are highlighted as precision-medicine advances entering the acne space.

Session: Mechanism of Action, Safety & Systemic Inflammation in JAK Inhibition
Date: Monday, March 30, 2026

Session Summary

Bunick presents a comprehensive reappraisal of JAK inhibitor safety and systemic inflammation, anchored in what he describes as a widespread misreading of the ORAL Surveillance study. Because the trial used an active comparator only—with no placebo arm—it cannot support conclusions about absolute cardiovascular risk for either tofacitinib or TNF-alpha inhibitors. The session will present transcriptomic evidence linking psoriasis and atopic dermatitis to shared atherosclerotic risk pathways, introduce his "diaper to diaper" hypothesis tracing systemic inflammation from growth stunting in pediatric AD to cardiovascular disease in adults, and close with a five-year comparative analysis of JAK inhibitor and IL-13-targeted safety data.

Session: Gross & Microscopic
Date: Friday, March 27, 2026
Title: Maintenance of IHS4 Response to Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa

Session Summary

Ackerman presents maintenance-of-response data for upadacitinib in moderate-to-severe HS using the IHS4 severity scoring system—extending previously published week-12 results to week 40 across patients achieving IHS4 55, 75, and 90 response thresholds. Durability is framed as the defining clinical imperative in HS: even patients without active lesions carry substantial anticipatory psychological burden between flares. Ackerman positions JAK1 inhibition as mechanistically well-suited to HS given its broad reach across the disease's heterogeneous cytokine architecture, and signals optimism for the emerging oral and adjuvant JAK inhibitor pipeline—including abrocitinib and povorcitinib—as the field moves beyond its current injectable-only approved options.